November 20, 2017
Authored and Edited by Nathan I. North; Kara Specht; Elizabeth D. Ferrill
In Sanofi v. Watson, No. 2016-2722, the Federal Circuit affirmed the district court’s decision, upholding induced infringement and validity of Sanofi’s patents covering compositions of, uses for, and methods for administering the drug dronedarone.
As to induced infringement, the district court found inducement based on the sale of a generic drug to physicians bearing “extensive information” on labels describing the intended use. The Federal Circuit affirmed the district court, finding inducement because the information on the labels included “information identifying the desired benefit for only patients with the patent-claimed risk factors.” The label thus “encouraged” administration of the drug to certain patients, inducing infringement of Sanofi’s patent.
With respect to validity, the district court found that one of ordinary skill in the art at the time of the invention would not have had a reasonable expectation of success that administration of the drug would reduce hospitalization. The Appellants argued that the district court applied too high a standard, requiring “near certainty” rather than a “reasonable expectation.” The Federal Circuit disagreed, holding that there was no clear error or indication that the district court used a higher standard.
Copyright © 2017 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.